This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tse, K C Articles by Chan, T M Search for Related Content PubMed PubMed Citation Articles by Tse, K C Articles by Chan, T M Social Bookmarking                         What's this?

A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

M F Lam

S CW Tang

C SO Tang

Nephrology Division, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

T M Chan

Nephrology Division, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong; dtmchan{at}hkucc.hku.hk

Persistent proteinuria in patients with quiescent lupus can result from membranous lupus nephritis and/or glomerular scarring following previous flares. This pilot study examined the effects of tacrolimus over two years in six patients with membranous/inactive lupus nephritis and persistent proteinuria despite angiotensin inhibition/blockade. Tacrolimus treatment reduced proteinuria and increased serum albumin (time effect, P = 0.047 and 0.032 respectively). Compared with baseline levels, proteinuria improved by more than 50% in five patients (83.3%) and hypoalbuminaemia was corrected in four patients. The efficacy was most prominent in four patients with biopsy-proven membranous lupus nephritis, whose protienuria improved by over 80%. One patient developed biopsy-proven chronic nephrotoxicity after 10 months of tacrolimus treatment, despite non-excessive blood levels. These data suggest that tacrolimus is an effective treatment for proteinuria due to membranous lupus nephritis, but should probably be reserved for patients who are refractory to other non-nephrotoxic treatments, in view of the potential risk of subclinical nephrotoxicity.

Key Words: calcineurine inhibitor • membranous lupus nephritis • proliferative lupus nephritis • tacrolimus

Lupus, Vol. 16, No. 1, 46-51 (2007)
DOI: 10.1177/0961203306073167


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M Ramos-Casals, M. Soto, M. Cuadrado, and M. Khamashta Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases Lupus, August 1, 2009; 18(9): 767 - 776. [Abstract] [PDF]

				C. Jennings, B. Kusler, and P. P. Jones Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo Innate Immunity, April 1, 2009; 15(2): 109 - 120. [Abstract] [PDF]

				C.-C. Szeto, B. C.-H. Kwan, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, K.-M. Chow, W. Gang, and P. K.-T. Li Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis Rheumatology, November 1, 2008; 47(11): 1678 - 1681. [Abstract] [Full Text] [PDF]

				H. Bao, Z.-H. Liu, H.-L. Xie, W.-X. Hu, H.-T. Zhang, and L.-S. Li Successful Treatment of Class V+IV Lupus Nephritis with Multitarget Therapy J. Am. Soc. Nephrol., October 1, 2008; 19(10): 2001 - 2010. [Abstract] [Full Text] [PDF]

				H. Tanaka, E. Oki, K. Tsugawa, K. Nonaka, K. Suzuki, and E. Ito Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study Lupus, November 1, 2007; 16(11): 896 - 900. [Abstract] [PDF]